GCP
BIO icon

GSA Capital Partners’s Bio-Rad Laboratories Class A BIO Stock Holding History

GSA Capital Partners’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-705
Closed -$214K – 1731
2025
Q4 		$214K Buy
+705
New +$220K 0.02% 1369
2022
Q4 		– Sell
-518
Closed -$216K – 1477
2022
Q3 		$216K Buy
+518
New +$258K 0.03% 1172
2022
Q1 		– Sell
-498
Closed -$376K – 1412
2021
Q4 		$376K Buy
+498
New +$373K 0.05% 786
2020
Q3 		– Sell
-824
Closed -$372K – 1245
2020
Q2 		$372K Buy
+824
New +$364K 0.21% 123
2019
Q4 		– Sell
-1,907
Closed -$635K – 1435
2019
Q3 		$635K Buy
+1,907
New +$622K 0.09% 404
2018
Q4 		– Sell
-3,568
Closed -$1.12M – 1358
2018
Q3 		$1.12M Sell
3,568
-225
-6% -$69.8K 0.06% 614
2018
Q2 		$1.09M Buy
3,793
+1,747
+85% +$482K 0.05% 701
2018
Q1 		$512K Sell
2,046
-1,826
-47% -$465K 0.03% 1047
2017
Q4 		$924K Buy
+3,872
New +$938K 0.06% 630
2017
Q3 		– Sell
-1,314
Closed -$297K – 1604
2017
Q2 		$297K Buy
+1,314
New +$286K 0.02% 1281
2016
Q3 		– Sell
-2,590
Closed -$370K – 1770
2016
Q2 		$370K Buy
+2,590
New +$369K 0.02% 1266
2016
Q1 		– Sell
-6,390
Closed -$886K – 1673
2015
Q4 		$886K Sell
6,390
-112
-2% -$15.5K 0.04% 788
2015
Q3 		$873K Buy
6,502
+4,503
+225% +$648K 0.04% 750
2015
Q2 		$301K Sell
1,999
-5,801
-74% -$830K 0.01% 1612
2015
Q1 		$1.05M Buy
7,800
+1,700
+28% +$211K 0.04% 824
2014
Q4 		$735K Buy
+6,100
New +$702K 0.05% 676
2014
Q1 		– Sell
-3,200
Closed -$396K – 1561
2013
Q4 		$396K Sell
3,200
-200
-6% -$24.4K 0.03% 1012
2013
Q3 		$400K Buy
3,400
+1,500
+79% +$177K 0.03% 936
2013
Q2 		$213K Buy
+1,900
New +$223K 0.03% 1056

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

GSA Capital Partners's BIO Position: Q1 2026 in Review

GSA Capital Partners sold out of Bio-Rad Laboratories Class A (BIO) in Q1 2026, closing a stake of 705 shares — an estimated $214K sold.

GSA Capital Partners first reported a position in BIO in Q2 2013 and held it in 19 quarters. The position peaked at $1.12M in Q3 2018. 395 funds tracked by Wall St. Rank hold BIO as of Q1 2026.

  • GSA Capital Partners reported no remaining Bio-Rad Laboratories Class A position as of Q1 2026 after selling out during the quarter.
  • GSA Capital Partners sold 705 Bio-Rad Laboratories Class A shares in Q1 2026, an estimated $214K.
  • GSA Capital Partners first reported a position in Bio-Rad Laboratories Class A in Q2 2013 and held it in 19 quarters.
  • GSA Capital Partners's Bio-Rad Laboratories Class A position peaked at $1.12M in Q3 2018.
  • 395 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.